| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8774817 | Nefrología | 2017 | 6 Pages |
Abstract
In summary, we conclude that new DAAs for the treatment of HCV in haemodialysis patients are highly effective with minimal adverse effects; it is a very important advance in HCV management. These patients are therefore expected to have a much better prognosis than they have had until very recently.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Soraya Abad, Almudena Vega, Diego Rincón, Eduardo Hernández, Evangelina Mérida, Nicolás MacÃas, Raquel Muñoz, Mónica Milla, Jose Luño, Juan Manuel López-Gómez,